Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Travere Therapeutics presented new biomarker data at ASN Kidney Week, indicating that FILSPARI (sparsentan) may alter the disease pathophysiology in patients with IgA nephropathy. The findings stem from the Phase 3 PROTECT Study, which highlights the dual mechanism of action of FILSPARI. This data could enhance understanding of treatment effects in IgAN.
Market Sentiment Analysis
POSITIVE FACTORS
New biomarker data presented at ASN Kidney Week.
Evidence suggests FILSPARI may modify disease pathophysiology.
Data from Phase 3 PROTECT Study supports findings.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
10.2%
average across 11 past catalysts
Lead asset
L-Citrulline
Phase 3 · Sickle Cell Disease
Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO.“These biomarker data provide new insight into how FILSPARI’s dual mechanism of action may modify the unde
Frequently Asked Questions
What is FILSPARI?
FILSPARI (sparsentan) is a treatment for IgA nephropathy.
What were the findings presented at ASN Kidney Week?
New biomarker data suggested FILSPARI may modify disease pathophysiology.
What study provided the new data?
The data came from the Phase 3 PROTECT Study.
Where was the presentation held?
The presentation took place at ASN Kidney Week in Denver, CO.